Work

In Vitro and In Vivo Characterization of Potent Antileishmanial Methionine Aminopeptidase 1 Inhibitors

Year: 2020

Type: article

Abstract: Leishmania major is the causative agent of cutaneous leishmaniasis (CL). No human vaccine is available for CL, and current drug regimens present several drawbacks, such as emerging resistance, severe toxicity, medium effectiveness, and/or high cost. Thus, the need for better treatment options against CL is a priority. In the present study, we validate the enzyme methionine aminopeptidase 1 of L. major (MetAP1 Lm ), a metalloprotease that catalyzes the removal of N-terminal methionine from peptides and proteins, as a chemotherapeutic target against CL infection.

Source: Antimicrobial Agents and Chemotherapy

DOI: 10.1128/aac.01422-19

Authors: Felipe Rodriguez, Sarah F. John, Eva Iniguez, Sebastian Montalvo, Karina Michael, Lyndsey White, Dong Liang, Omonike A. Olaleye, Rosa A. Maldonado

Institutions: The University of Texas at El Paso, Harris Health System, Texas Southern University

Language: English

Topic: Research on Leishmaniasis Studies

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Institute of General Medical Sciences, National Center for Research Resources, National Institute on Minority Health and Health Disparities

Awards: G15967318, G2177492154, Phase II of BUILDing SCHOLARS, G265186493, G2804015964, G3916269333, G5149680960, G5277383200, G5284985403, G623418118, G7364278372, G8846023593, Phase II of BUILDing SCHOLARS - Research Enrichment Core, G9000310814, Center for Biomedical and Health Research at TSU

OpenAlex ID: W3012358147

FWCI: 1.892

Cites: 49

Cited by: 18

Related to: 10